ADULT-ONSET STILL'S DISEASE: A FORGOTTEN MYTH

Main Article Content

Aziz un Nisa
Sultan Zeb
Ibrahim
Ayesha Ghazanfar

Abstract

Adult-onset Still’s disease (AOSD), also known as Wissler-Fanconi syndrome is a rare systemic disorder. Symptoms usually include fever, joint pain, and rash. The diagnosis of ASOD is mostly clinical and excludes other possible causes. In this case report, a 25 years old gentleman, who in the recent past was diagnosed and treated with septic and reactive arthritis. He presented to us with a salmon-colored rash along with arthritis and was diagnosed as AOSD on the basis of clinical criteria, leukocytosis, raised inflammatory markers i.e., serum ferritin after the exclusion of other conditions.

Article Details

How to Cite
1.
Aziz un Nisa, Sultan Zeb, Ibrahim, Ayesha Ghazanfar. ADULT-ONSET STILL’S DISEASE: A FORGOTTEN MYTH. J Postgrad Med Inst [Internet]. 2022 Mar. 31 [cited 2022 Jul. 6];36(1):47-50. Available from: https://jpmi.org.pk/index.php/jpmi/article/view/2943
Section
Case Report

References

Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60.9.

Owlia MB, Mehrpoor G. Adult-onset Stills disease: A review. Indian J Med Sci. 2009; 63(5):207-21.

Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(1):6–14. DOI.org/10.3109/07853890.2014.971052

Kim H-A, Han JH, Kim W-J, Noh HJ, An J-M, Yim H, et al. TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still’s a disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17(8):1342. DOI.org/10.3390/ijms17081342

Wang Z, Chi H, Sun Y, Teng J, Feng T, Liu H, et al. Serum sTREM-1 in adult-onset Still’s a disease: a novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology (Oxford). 2020;59(11):3293–302. DOI.org/10.1093/rheumatology/keaa135

Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–18.DOI.org/10.1038/s41584-018-0081-x

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for the classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–30.

Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: Multicenter study of 41 patients and literature review. Medicine (Baltimore) . 2015;94(39):e1554. DOI.org/10.1097/MD.0000000000001554

Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P. Canakinumab for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol. 2020;16(2):129–38. DOI.org/10.1080/1744666X.2019.1707664

Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol . 2017;36(12):2839–45. DOI.org/10.1007/s10067-017-3830-3